» Articles » PMID: 38853763

Association of APOE Genotype and Cerebrospinal Fluid Aβ and Tau Biomarkers with Cognitive and Motor Phenotype in Amyotrophic Lateral Sclerosis

Abstract

Objective: Little is known about amyotrophic lateral sclerosis (ALS)-nonspecific cognitive deficits - most notably memory disturbance - and their biological underpinnings. We investigated the associations of the Alzheimer's disease (AD) genetic risk factor APOE and cerebrospinal fluid (CSF) biomarkers Aβ and tau proteins with cognitive and motor phenotype in ALS.

Methods: APOE haplotype was determined in 281 ALS patients; for 105 of these, CSF levels of Aβ42, Aβ40, total tau (T-tau), and phosphorylated tau (P-tau181) were quantified by chemiluminescence enzyme immunoassay (CLEIA). The Edinburgh Cognitive and Behavioural ALS Screen (ECAS) was employed to evaluate the neuropsychological phenotype.

Results: APOE-E4 allele was associated with worse ECAS memory score (median, 14.0 in carriers vs. 16.0 in non-carriers) and lower CSF Aβ42 (-0.8 vs. 0.1, log-transformed values) and Aβ42/40 ratio (-0.1 vs. 0.3). Some 37.1% of ALS patients showed low Aβ42 levels, possibly reflecting cerebral Aβ deposition. While lower Aβ42/40 correlated with lower memory score (β = 0.20), Aβ42 positively correlated with both ALS-specific (β = 0.24) and ALS-nonspecific (β = 0.24) scores. Although Aβ42/40 negatively correlated with T-tau (β = -0.29) and P-tau181 (β = -0.33), we found an unexpected positive association of Aβ42 and Aβ40 with both tau proteins. Regarding motor phenotype, lower levels of Aβ species were associated with lower motor neuron (LMN) signs (Aβ40: β = 0.34; Aβ42: β = 0.22).

Conclusions: APOE haplotype and CSF Aβ biomarkers are associated with cognitive deficits in ALS and particularly with memory impairment. This might partly reflect AD-like pathophysiological processes, but additional ALS-specific mechanisms could be involved.

Citing Articles

Impact of APOE and MAPT genetic profile on the cognitive functions among Amyotrophic Lateral Sclerosis Tunisian patients.

Sghaier I, Kacem I, Ratti A, Takout K, Abida Y, Peverelli S J Neural Transm (Vienna). 2025; 132(4):609-618.

PMID: 39751824 DOI: 10.1007/s00702-024-02870-3.


Association of APOE genotype and cerebrospinal fluid Aβ and tau biomarkers with cognitive and motor phenotype in amyotrophic lateral sclerosis.

Maranzano A, Verde F, Dubini A, Torre S, Colombo E, Doretti A Eur J Neurol. 2024; 31(9):e16374.

PMID: 38853763 PMC: 11295165. DOI: 10.1111/ene.16374.

References
1.
Cedarbaum J, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B . The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999; 169(1-2):13-21. DOI: 10.1016/s0022-510x(99)00210-5. View

2.
Devine M, Ballard E, ORourke P, Kiernan M, McCombe P, Henderson R . Targeted assessment of lower motor neuron burden is associated with survival in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2015; 17(3-4):184-90. DOI: 10.3109/21678421.2015.1125502. View

3.
Maranzano A, Verde F, Dubini A, Torre S, Colombo E, Doretti A . Association of APOE genotype and cerebrospinal fluid Aβ and tau biomarkers with cognitive and motor phenotype in amyotrophic lateral sclerosis. Eur J Neurol. 2024; 31(9):e16374. PMC: 11295165. DOI: 10.1111/ene.16374. View

4.
Gentleman S, Nash M, Sweeting C, Graham D, Roberts G . Beta-amyloid precursor protein (beta APP) as a marker for axonal injury after head injury. Neurosci Lett. 1993; 160(2):139-44. DOI: 10.1016/0304-3940(93)90398-5. View

5.
van Rheenen W, van der Spek R, Bakker M, van Vugt J, Hop P, Zwamborn R . Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nat Genet. 2021; 53(12):1636-1648. PMC: 8648564. DOI: 10.1038/s41588-021-00973-1. View